Literature DB >> 12370767

Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma.

Carsten Boltze1, Albert Roessner, Olfert Landt, Reinhard Szibor, Brigitte Peters, Regine Schneider-Stock.   

Abstract

The p53 tumor suppressor gene is altered in human cancer. A common polymorphism occurs at codon 72 of exon 4, with two alleles encoding either arginine (CGC) or proline (CCC). No data exist about the association of a distinct codon 72 variant with the histological subtypes of thyroid carcinoma. We developed a new one-step real-time PCR assay on the LightCycler to detect codon 72 polymorphism in the p53 gene. We studied 21 papillary, 18 follicular and 22 anaplastic thyroid carcinomas and compared them with 15 adenomas and 36 normal thyroid tissues (controls); moreover, we compared the cases for histological, clinical and demographic variables and genotype prevalence. In controls, the frequency of the three genotypes Arg/Arg, Arg/Pro, and Pro/Pro was 41.7, 50.0 and 8.3%, respectively. The homozygous proline was not found in benign thyroid adenomas and differentiated thyroid carcinomas. In contrast, all undifferentiated thyroid carcinomas (100%) had the homozygous proline phenotype. The frequency of the two other genotypes Arg/Arg and Arg/Pro was 66.7% and 33.3% in adenomas, 81.0% and 19.0% in papillary thyroid carcinomas, and 83.3% and 16.7% in follicular thyroid carcinomas, respectively. Comparing the genotypes with tumor stage, no correlation was found. However, lymph node and distant metastases status showed a statistically significant prevalence for the homozygous phenotypes Arg/Arg and Pro/Pro. There was no association between a special genotype and age and sex. We conclude that homozygous proline is a potential risk factor favoring the development of an undifferentiated thyroid carcinoma, and that the homozygous phenotypes at codon 72 of p53 are associated with a poorer prognosis of thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370767

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk.

Authors:  Fang Wang; Peng Wang; Bin Wang; Zheng-Ju Fu; Ying Yuan; Sheng-Li Yan; Wen-Juan Zhao; Yan-Gang Wang
Journal:  Tumour Biol       Date:  2013-12-28

2.  Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis.

Authors:  Bo Wu; Dan Guo; Ying Guo
Journal:  Tumour Biol       Date:  2013-09-15

3.  TP53 polymorphism may contribute to genetic susceptibility to develop Hashimoto's thyroiditis.

Authors:  R M Ruggeri; T M Vicchio; S Giovinazzo; R Certo; A Alibrandi; F Trimarchi; S Benvenga; M Trovato
Journal:  J Endocrinol Invest       Date:  2015-05-03       Impact factor: 4.256

4.  p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases.

Authors:  Rong-Hsing Chen; Chwen-Tzuei Chang; Tzu-Yuan Wang; Wen-Liang Huang; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

5.  Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients.

Authors:  Roghayeh Dehghan; Mohammad Ali Hosseinpour Feizi; Nasser Pouladi; Esmaeil Babaei; Vahid Montazeri; Ashraf Fakhrjoo; Ayda Sedaei; Parvin Azarfam; Masoumeh Nemati
Journal:  Pathol Oncol Res       Date:  2014-11-20       Impact factor: 3.201

Review 6.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

7.  P53 and expression of immunological markers may identify early stage thyroid tumors.

Authors:  Marjory Alana Marcello; Elaine Cristina Morari; Lucas Leite Cunha; Aline Carolina De Nadai Silva; Dirce Maria Carraro; André Lopes Carvalho; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Clin Dev Immunol       Date:  2013-09-19

8.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

9.  In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.

Authors:  Isrid Sturm; Andrew G Bosanquet; Michael Hummel; Bernd Dörken; Peter T Daniel
Journal:  BMC Cancer       Date:  2005-08-18       Impact factor: 4.430

10.  MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians.

Authors:  Joerg Bittenbring; Frédérique Parisot; Alain Wabo; Monika Mueller; Lynn Kerschenmeyer; Markus Kreuz; Lorenz Truemper; Olfert Landt; Alain Menzel; Michael Pfreundschuh; Klaus Roemer
Journal:  BMC Cancer       Date:  2008-04-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.